Jiangsu Vcare and Geneseeq Form Strategic Partnership for NTRK Companion Diagnostics
Published Time:
2024-07-02 17:28
Source:
On July 2, 2024, Jiangsu Vcare and Geneseeq signed a strategic cooperation agreement in Nanjing’s Jiangbei New District. The collaboration will focus on the joint development and future commercialization of a companion diagnostic kit for the NTRK inhibitor VC004.
VC004, a second-generation NTRK inhibitor independently developed by Jiangsu Vcare, has demonstrated excellent in vitro and in vivo activity, favorable pharmacokinetic properties, good tolerability, and high response rates in early clinical studies. With no second-generation NTRK inhibitors currently approved in China, VC004 is poised to fill this critical gap.
Jiangsu Vcare: Specializes in the development of innovative drugs and advanced therapies, with deep expertise in R&D and market expansion across oncology, cardiovascular and cerebrovascular diseases, autoimmune disorders, and other therapeutic areas. The company has developed multiple clinical-stage Class I innovative drugs and clinical solutions.
Geneseeq: A leading Chinese precision oncology testing company, Geneseeq possesses advanced high-throughput gene sequencing technologies and extensive experience in diagnostic kit development and regulatory approval. It is the only domestic enterprise with two NGS-based innovative medical device reagent products.
The partnership will leverage the complementary strengths of both parties to accelerate the development and commercialization of VC004’s companion diagnostics, promote the clinical application of NTRK1/2/3 gene fusion detection, and deliver transformative benefits to cancer patients.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: “VC004, our self-developed next-generation NTRK inhibitor, is currently in a critical Phase II clinical trial in China. We are honored to partner with our ‘neighbor’ Geneseeq at this pivotal stage. Geneseeq has achieved remarkable success in translating gene sequencing technologies into clinical applications. This collaboration will integrate VC004’s research advancements with Geneseeq’s diagnostic expertise, profoundly addressing unmet clinical needs. We look forward to contributing to medical progress and human health through this partnership.”
Dr. Wang Xiaonan, Co-founder and Chief Technology Officer of Geneseeq, remarked: “As fellow enterprises in Nanjing’s Jiangbei New District, Geneseeq and Jiangsu Vcare have collaborated for years. Both companies prioritize innovation, driven by clinical demand, to achieve high-quality development. I am confident that this strategic alliance will accelerate the efficiency of innovative drug R&D and clinical application, ultimately providing patients with more therapeutic options and greater survival benefits.”
Related News
28
2025
/
04
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful enrollment of the first participant in its Phase II clinical trial for VC005 topical gel, a self-developed next-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD). The trial aims to evaluate the efficacy of VC005 gel in adult patients with mild-to-moderate AD, providing a critical data for dose selection in future clinical studies and further assesses the drug's safety profile.
View Details
11
2025
/
04
Recently, following joint review by Nanjing Jiangbei New Area Sci-Tech Bureau and Nanjing Municipal Science and Technology Bureau, the"Nanjing Key Laboratory for Artificial Intelligence (AI) Drug Design"established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was approved as a 2025 Nanjing Key Laboratory. This marks authoritative recognition of Jiangsu Vcare’s scientific capabilities, with the Lab having achieved significant progress in drug design and molecular discovery.
View Details
26
2025
/
03
Jiangsu Vcare Launches Phase II Trial for VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
On March 26, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) officially launched the Phase II clinical trial for its self-developed, highly selective JAK1 inhibitor VC005 gel for the topical treatment of mild-to-moderate atopic dermatitis (AD). The completed Phase I clinical study of VC005 gel demonstrated excellent safety and significant efficacy.
View Details
27
2025
/
01
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
View Details
26
2025
/
01
In January 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that its self-developed next-generation anti-resistant TRK inhibitor VC004 capsule has officially entered the domestic NDA preparation phase, initiating pre-NDA communications with regulatory authorities. Marking this milestone, Jiangsu Vcare has joined the top tier of domestic self-developed drugs targeting this pathway at remarkable speed.
View Details
22
2025
/
01
Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn